Protocol Ledger

NCT07546929 · Phase II · RECRUITING

HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Diabetes

Interventional Phase II clinical trial protocol NCT07546929 sponsored by Housey Healthcare ULC in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-02-03 Enrollment: 300 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07546929
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)300 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07546929
Protocol FieldVerified Registry Value
NCT IdentifierNCT07546929
Consolidated Lead SponsorHousey Healthcare ULC
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment300 participants (ESTIMATED)
Registered Start Date2023-02-03
WhyStopped ClassificationNot Stopped

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI